Hepatectomy
Conditions
Interventions
Lidocaine group:1% lidocaine(1.5mg/kg) is administrated intravenously over ten minutes at the induction of general anesthesia, followed by continuous infusion of 1% lidocaine at 1.5mg/kg/h throughout
Conventional analgesia group:During anesthesia and maintenance, the same amount of normal saline is used, replacing the corresponding dose of lidocaine. After the operation, the patient controlled int
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years; 2. American Society of Anesthesiologists(ASA) I/ III; 3. BMI 18 to 30; 4. Patients who undergo elective resection of primary hepatocellular carcinoma.
Exclusion criteria
Exclusion criteria: 1. Patients with primary liver cancer complicated with malignant tumors of other organs (such as lung, kidney, intestinal tract, etc.); 2. Long-term opioid use, alcohol or drug abuse or any of the drugs used in this study were contraindicated and allergic for patients; 3. Patients with severe hepatic and renal dysfunction (total bilirubin > 1.46mg/dl, glomerular filtration rate <30ml/min /1.73? or end-stage renal disease); 4. Severe heart disease (severe heart block (including sinoatrial, atrioventricular, and intraventricular block); Severe heart failure (ejection fraction < 20%); Sinus bradycardia; Patients with Adams-Stokes syndrome, preexcitation syndrome, etc. 5. Patients with a history of uncontrolled seizures or acute porphyria; 6. Long-term use of cimetidine and beta-blockers (lidocaine metabolism is inhibited through the liver, resulting in increased blood concentration of the drug, which can lead to adverse cardiac and nervous system reactions). 7. Patients treated with drugs that are contraindicated with lidocaine (phenobarbital, thiopental, sodium nitroprusside, mannitol, amphotericin B, ampicillin, mesonotal, sulfadiazine sodium); Patients who are using enoxacin, lomefloxacin, norfloxacin, and prulifloxacin; 8. Patients who have taken other experimental drugs or participated in other clinical trials within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of moderate to severe pain at the active states; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of moderate to severe pain at resting states;Incidence of moderate to severe pain at the resting and active states;Satisfaction score on postoperative 3 days;The time of bowel function recovery;NK cells, IL-6, IL-8, C3a, C5a, P (CD62P)-selectin, TNF-a and C-reactive protein are measured in peripheral blood;Plasma lidocaine concentration and the Incidence of side effects with lidocaine;Liver and kidney function changes;Hospitalization days and hospitalization expenses;The incidence of chronic pain;Changes in tumor markers and the relapse - free survival rate, overall survival rate, disability-free rate survival rates are based on CT, MRI, or ultrasound diagnosis after surgery;Dosage of opioids and side effects within 24h, 48h and 72h after surgery;Respiratory complications 7 days after the operation; | — |
Countries
China
Contacts
Public ContactChunling Jiang
West China Hospital, Sichuan University
Outcome results
None listed